| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2022: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2021: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2020: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2019: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
|
|---|
| Outline of Final Research Achievements |
Immune responses are preserved by delicate balance of various cell types and cytokines to prevent the development of autoimmune diseases and allergy. Majority of previous studies for developing therapeutic approaches against these diseases have focused on targeting the pathogenic cell populations. In contrast, we herein focus on immune regulatory B cells and plasma blasts to preserve immune balance, which can prevent the development of pathogenic cells and also induce the termination of inflammatory responses in inflammatory bowel disease that is increasing continuously in Japan. We hope this project, if fully completed, would provide a novel insight into the development of an innovative therapeutic strategy that aims to complete cure rather than induction and maintenance of remission for inflammatory bowel disease.
|
